Skip To Main Content
Mustafa Murat Midik on Muck Rack

Mustafa Murat Midik

Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Mustafa Murat

Contact Mustafa Murat, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

First Line Durvalumab-Tremelimumab in Advanced Hepatocellular Carcinoma: Real-World Data From Turkey

|
By Gokhan Sahin, Mustafa Murat Midik, Bekir Mert Durukan
| Preprints.org
You are already at the latest version Backround:Hepatocellular carcinoma (HCC) is the most common neoplasm to cause death. First line treatment options are still challenging for HCC. STRIDE regimen (durvalumab/tremelimumab) showed improved median overall survival (OS) rates however did not make differ significantly in median progression-free survival (PFS) rate. Method:We reviewed outcomes of patients with HCC who initiated durval-umab/tremelimumab between 2020 and 2024, across 18 institutions.
Open in Who Shared Issue with article?
See all 1 articles